NEWAMSTERDAM PHARMA CO NV (NAMS)
NL00150012L7 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to NAMS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 37.89. This target is 140.7% above the current price.
NAMS was analyzed by 16 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about NAMS.
In the previous month the buy percentage consensus was at a similar level.
NAMS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-09-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-28 | Needham | Initiate | Buy |
| 2024-07-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-06-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-15 | TD Cowen | Initiate | Buy |
| 2024-03-14 | ScotiaBank | Initiate | Sector Outperform -> Sector Outperform |
| 2024-03-13 | ScotiaBank | Initiate | Sector Outperform |
| 2024-02-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-01-18 | Guggenheim | Initiate | Buy |
| 2024-01-16 | Piper Sandler | Initiate | Overweight |
| 2023-10-30 | RBC Capital | Initiate | Outperform |
| 2023-04-03 | Credit Suisse | Maintains | Outperform |
| 2023-01-06 | Credit Suisse | Initiate | Outperform |
| 2022-12-20 | SVB Leerink | Initiate | Outperform |
| 2022-12-19 | William Blair | Initiate | Outperform |
| 2022-12-19 | Jefferies | Initiate | Buy |